Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 20 03 2020
revised: 25 04 2020
accepted: 27 04 2020
pubmed: 10 6 2020
medline: 5 1 2021
entrez: 10 6 2020
Statut: ppublish

Résumé

During the last few years, determination of microstatellite instability (MSI) status has become a routine part of clinical practice, essentially to detect Lynch syndrome. Recently, MSI testing has increased with the development of immunotherapy and has expanded to a large panel of solid tumours. The aim of our work was to evaluate a fully automated system developed by Biocartis, the Idylla MSI Test, which performs an MSI analysis within 150 min. A comparison between pentaplex PCR, immunohistochemistry and Idylla MSI Test was performed in 53 colorectal carcinoma samples, 7 small intestine adenocarcinomas, 15 duodenal and pancreatic adenocarcinomas, 16 gastric tumours, 15 endometrial adenocarcinomas, 5 ovarian carcinomas and 4 cases of urinary tract tumours using extracted DNA. Limit-of-detection (LOD) experiment was also done using a commercial DNA known to harbour MSI phenotype. The overall sensitivity was 94% and the overall specificity was 100%. Two invalid and three false-negative results were observed. Our experiments showed that the amount of DNA loaded into the cartridge was decisive and should be superior to 25 ng. LOD comprised between 4% and 8%. Overall, we have demonstrated that the Idylla MSI Test is a rapid and valid option to detect MSI phenotype which can be used in a large panel of solid tumours.

Identifiants

pubmed: 32513848
pii: jclinpath-2020-206581
doi: 10.1136/jclinpath-2020-206581
doi:

Substances chimiques

DNA, Neoplasm 0

Types de publication

Comparative Study Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-42

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Adrien Pécriaux (A)

Department of Pathology, CHU Henri Mondor, Créteil, France.

Loetitia Favre (L)

Department of Pathology, CHU Henri Mondor, Créteil, France.
Université Paris-Est Créteil Val de Marne Faculté de médecine, Creteil, France.

Julien Calderaro (J)

Department of Pathology, CHU Henri Mondor, Créteil, France.
Université Paris-Est Créteil Val de Marne Faculté de médecine, Creteil, France.

Cécile Charpy (C)

Department of Pathology, CHU Henri Mondor, Créteil, France.

Jonathan Derman (J)

Department of Pathology, CHU Henri Mondor, Créteil, France.

Anaïs Pujals (A)

Department of Pathology, CHU Henri Mondor, Créteil, France anais.pujals@aphp.fr.
Université Paris-Est Créteil Val de Marne Faculté de médecine, Creteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH